EP Patent

EP3278801A4 — Medicinal composition containing mirabegron

Assigned to Astellas Pharma Inc · Expires 2018-11-14 · 8y expired

What this patent protects

Patent listed against Myrbetriq.

Drugs covered by this patent

Myrbetriq (MIRABEGRON) · Apgdi

Patent Metadata

Patent number: EP3278801A4
Jurisdiction: EP
Classification: —
Expires: 2018-11-14
Drug substance claim: No
Drug product claim: No
Assignee: Astellas Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.